File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Chemotherapy response in East Asian non-small cell lung cancer patients harboring wild-type or activating mutation of epidermal growth factor receptors

TitleChemotherapy response in East Asian non-small cell lung cancer patients harboring wild-type or activating mutation of epidermal growth factor receptors
Authors
Issue Date2010
Citation
Journal of Thoracic Oncology, 2010, v. 5 n. 9, p. 1424-1429 How to Cite?
AbstractIntroduction: Previous exploratory analysis of epidermal growth factor receptor (EGFR) mutational status in tumor samples from randomized clinical studies suggested that patients with activating mutation of the EGFR had better survival than those harboring wild-type EGFR. Methods: We analyzed the EGFR sequence of tumor samples from advanced stage non-small cell lung cancer patients previously participated in treatment clinical trials. Responses to chemotherapy and survival of EGFR mutation-positive or-negative patients were compared. Results: Tumor samples from 122 patients were available for analysis. EGFR mutation was present in 58 patients (47.5%). In 105 stage IIIB/IV patients, there was a nonstatistically significant trend toward a higher chemotherapy response rate of patients with mutated EGFR than those with wild-type EGFR (44.6% versus 30.6%, p = 0.162). Female, never-smoking, and adenocarcinoma patients lived longer than male (p = 0.0139), smoking (p = 0.0045), or nonadenocarcinoma (p = 0.0151) patients. There was no difference in the survival of patients with mutated or wild-type EGFR (p = 0.2159). There was no difference in progression-free survival of first-line chemotherapy between patients with wild-type or mutation in EGFR (6.6 months versus 6.1 months). Conclusion: There is a nonstatistically significant trend toward a higher chemotherapy response rate in patients with mutated EGFR than those with wild-type EGFR. EGFR gene mutation is not a predictive biomarker for progression-free and overall survival to cytotoxic chemotherapy in East Asians with advanced non-small cell lung cancer. © 2010 by the International Association for the Study of Lung Cancer.
Persistent Identifierhttp://hdl.handle.net/10722/192679
ISSN
2015 Impact Factor: 5.04
2015 SCImago Journal Rankings: 2.597

 

DC FieldValueLanguage
dc.contributor.authorLin, C-Cen_US
dc.contributor.authorHsu, H-Hen_US
dc.contributor.authorSun, C-Ten_US
dc.contributor.authorShih, J-Yen_US
dc.contributor.authorLin, Z-Zen_US
dc.contributor.authorYu, C-Jen_US
dc.contributor.authorChen, GGen_US
dc.contributor.authorHsin, MKYen_US
dc.contributor.authorLam, KCen_US
dc.contributor.authorLeung, Len_US
dc.contributor.authorYang, C-Hen_US
dc.contributor.authorMok, Ten_US
dc.date.accessioned2013-11-20T04:55:14Z-
dc.date.available2013-11-20T04:55:14Z-
dc.date.issued2010en_US
dc.identifier.citationJournal of Thoracic Oncology, 2010, v. 5 n. 9, p. 1424-1429en_US
dc.identifier.issn1556-0864en_US
dc.identifier.urihttp://hdl.handle.net/10722/192679-
dc.description.abstractIntroduction: Previous exploratory analysis of epidermal growth factor receptor (EGFR) mutational status in tumor samples from randomized clinical studies suggested that patients with activating mutation of the EGFR had better survival than those harboring wild-type EGFR. Methods: We analyzed the EGFR sequence of tumor samples from advanced stage non-small cell lung cancer patients previously participated in treatment clinical trials. Responses to chemotherapy and survival of EGFR mutation-positive or-negative patients were compared. Results: Tumor samples from 122 patients were available for analysis. EGFR mutation was present in 58 patients (47.5%). In 105 stage IIIB/IV patients, there was a nonstatistically significant trend toward a higher chemotherapy response rate of patients with mutated EGFR than those with wild-type EGFR (44.6% versus 30.6%, p = 0.162). Female, never-smoking, and adenocarcinoma patients lived longer than male (p = 0.0139), smoking (p = 0.0045), or nonadenocarcinoma (p = 0.0151) patients. There was no difference in the survival of patients with mutated or wild-type EGFR (p = 0.2159). There was no difference in progression-free survival of first-line chemotherapy between patients with wild-type or mutation in EGFR (6.6 months versus 6.1 months). Conclusion: There is a nonstatistically significant trend toward a higher chemotherapy response rate in patients with mutated EGFR than those with wild-type EGFR. EGFR gene mutation is not a predictive biomarker for progression-free and overall survival to cytotoxic chemotherapy in East Asians with advanced non-small cell lung cancer. © 2010 by the International Association for the Study of Lung Cancer.en_US
dc.languageengen_US
dc.relation.ispartofJournal of Thoracic Oncologyen_US
dc.titleChemotherapy response in East Asian non-small cell lung cancer patients harboring wild-type or activating mutation of epidermal growth factor receptorsen_US
dc.typeArticleen_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1097/JTO.0b013e3181e9db73en_US
dc.identifier.pmid20631634-
dc.identifier.scopuseid_2-s2.0-77956263560en_US
dc.identifier.volume5en_US
dc.identifier.issue9en_US
dc.identifier.spage1424en_US
dc.identifier.epage1429en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats